We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Critique |

Cancer Antigens 19-9 and 125 in the Differential Diagnosis of Pancreatic Mass Lesions—Invited Critique

Rosa Hwang, MD; Douglas Evans, MD
Arch Surg. 2006;141(10):974. doi:10.1001/archsurg.141.10.974.
Text Size: A A A
Published online


Originally described as a marker for colorectal cancer,1 CA 19-9 has become the gold standard serologic marker for pancreatic cancer, with reported sensitivity and specificity as high as 87% and 98%, respectively.2 However, known limitations of CA19-9 as a biomarker include the following: (1) elevation of CA 19-9 levels with hyperbilirubinemia of both malignant and benign causes; and (2) falsely low CA 19-9 levels in individuals with the Le(a−b−) blood group who do not synthesize CA 19-9 despite having advanced pancreatic cancer. Because the CA 19-9 antigen is also a sialylated Lea blood group antigen,3 individuals with the Le(a−b−) blood group are deficient in a fucosyltransferase specified by the Le gene that is involved in the synthesis of the CA 19-9 antigen. About 5% to 14% of the population genotypically have the Le(a−b−) blood group and thus are unable to synthesize CA 19-9.4 In an attempt to improve the diagnostic accuracy of CA 19-9, the study by Ćwik and colleagues evaluates the combination of CA 19-9 and CA 125, which is a serum marker that is often used to diagnose ovarian cancer.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Toward Curative Fluorescence-Guided Surgery of Pancreatic Cancer. Hepatogastroenterology 2015;62(139):715-22.
MABS: targeted therapy tailored to the patient's need. Br J Nurs 2015;24(16 Suppl 1):S4-13.

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Breast Cancer

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Cancer, Family History